Co-Diagnostics Advances Ebola Assay Development with CoSara Amid Global Health Emergency
CODX has more than doubled off its 52-week low of $1.26 on elevated volume (1.9× avg).
Summary
Co-Diagnostics is advancing its PCR assay development strategy for the Bundibugyo virus (Ebola) with its Indian joint venture, CoSara Diagnostics. This development comes as the World Health Organization recently declared the Ebola outbreak a public health emergency. The company faces significant financial challenges, including a 'going concern' warning, substantial losses, and recent dilutive financing through an S-3 shelf registration for $150 million and a $3 million private placement. While this product development could provide a future revenue stream and address a critical global need, the product is still in development and not yet available for sale, limiting immediate financial impact.
At the time of this announcement, CODX was trading at $6.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.3M. The 52-week trading range was $1.26 to $46.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.